Zygomycosis (mucormycosis): emerging clinical importance and new treatments
- 1 December 2004
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Infectious Diseases
- Vol. 17 (6), 517-525
- https://doi.org/10.1097/00001432-200412000-00003
Abstract
New importance has been given to zygomycosis, as what was uncommon is no longer. Zygomycosis (mucormycosis) typically occurs in patients with leukemia, with solid-organ transplants or bone marrow transplants, with diabetic ketoacidosis, in those who have received steroids or are neutropenic, and after desferioxamine therapy. Often, both diagnostic and therapeutic measures are performed too late and are inadequate. Mortality rates may be as high as 80% in infected transplant recipients. Zygomycosis also appears to have made a subtle increase in incidence: up to 8% in autopsied patients with leukemia, and 2% in allogenic bone marrow transplant patients. Most infections are acquired by inhalation, ingestion, or trauma. They rapidly infarct blood vessels, resulting in necrosis of surrounding tissue. Over the past few years, new diagnostic procedures, susceptibility tests, and drugs have entered the clinic, and these advances are discussed in the review. With the rise in number of cases of ‘zygomycosis’, new scrutiny has been directed at the terms ‘zygomycosis’ and ‘mucormycosis’. This review explains their differences and the attending relevance for the clinician. Diagnostic methods include new molecular detection assays and new susceptibility testing options. New treatment options will soon exist with triazole antifungal agents. The first one expected to enter clinical practice is posaconazole in 2005. Its metabolism, pharmacokinetics, in-vitro and in-vivo activity, and clinical study results are described. Finally, we present our approach to zygomycosis. This review discusses key elements to laboratory diagnostic and susceptibility procedures and new treatment options.Keywords
This publication has 53 references indexed in Scilit:
- Experience with the MicroSeq D2 Large-Subunit Ribosomal DNA Sequencing Kit for Identification of Filamentous Fungi Encountered in the Clinical LaboratoryJournal of Clinical Microbiology, 2004
- Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatmentClinical Microbiology & Infection, 2004
- Infections due to emerging and uncommon medically important fungal pathogensClinical Microbiology & Infection, 2004
- Opportunistic Mycelial Fungal Infections in Organ Transplant Recipients: Emerging Importance of Non-Aspergillus Mycelial FungiClinical Infectious Diseases, 2003
- Diagnosis of Invasive Septate Mold InfectionsAmerican Journal of Clinical Pathology, 2003
- Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2002
- Histologic Features of ZygomycosisArchives of Pathology & Laboratory Medicine, 2001
- Zygomycosis in the 1990s in a Tertiary-Care Cancer CenterClinical Infectious Diseases, 2000
- Zygomycetes in Human DiseaseClinical Microbiology Reviews, 2000
- Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: A case report and review of the literaturePediatric Pulmonology, 1997